Eden Biodesign Signs Marketing Services Agreement with Human Genome Sciences
News Aug 19, 2008
Under the terms of the agreement, Eden Biodesign will use its expertise and global presence in the biopharmaceutical contract manufacturing market to assist HGS in identifying new manufacturing clients for its large scale commercial cell culture production facilities located in Rockville, MD.
Both companies will use their combined expertise in process development, process scale-up, technology transfer, analytical and international regulatory support for biopharmaceuticals to provide customers with transition into cGMP manufacturing at scales up to 20,000L and access to commercial production capacity for biopharmaceuticals derived from mammalian cell culture.
“This alliance is particularly significant for Eden Biodesign and we are delighted that such a prestigious company as Human Genome Sciences has recognized Eden Biodesign’s technical excellence, global marketing reach and strong track record” commented Dr. Crawford Brown, Chief Executive Officer of Eden Biodesign.
“In addition to our process development and clinical scale cGMP production services, our growing portfolio of successful clients may now also have seamless access to Human Genome Sciences’ world leading expertise in late-stage process development and state-of-the-art large scale production facilities as their products progress towards, and in to, commercial launch”.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE